BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamamoto K, Ishigami M, Honda T, Takeyama T, Ito T, Ishizu Y, Kuzuya T, Hayashi K, Goto H, Hirooka Y. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatol Int 2019;13:234-44. [DOI: 10.1007/s12072-019-09932-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhang M, Xu X, Liu W, Zhang Z, Cheng Q, Yang Z, Liu T, Liu Y, Ning Q, Chen T, Qi J. Proton Pump Inhibitor Therapy Increases the Risk of Spontaneous Bacterial Peritonitis in Patients with HBV-Related Acute-on-Chronic Liver Failure. Adv Ther 2021;38:4675-94. [PMID: 34308513 DOI: 10.1007/s12325-021-01844-1] [Reference Citation Analysis]
2 Wehmeyer MH, Horvatits T, Buchholz A, Krause L, Walter S, Zapf A, Lohse AW, Kluwe J; STOPPIT-trial group. Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial. Trials 2022;23:302. [PMID: 35414106 DOI: 10.1186/s13063-022-06232-w] [Reference Citation Analysis]
3 Le Bastard Q, Berthelot L, Soulillou JP, Montassier E. Impact of non-antibiotic drugs on the human intestinal microbiome. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34225544 DOI: 10.1080/14737159.2021.1952075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yamamoto K, Ishizu Y, Honda T, Ito T, Imai N, Nakamura M, Kawashima H, Kitaura Y, Ishigami M, Fujishiro M. Patients with low muscle mass have characteristic microbiome with low potential for amino acid synthesis in chronic liver disease. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-07810-3] [Reference Citation Analysis]
5 Mak LY, Fung J. Proton pump inhibitors in chronic liver disease: accomplice or bystander? Hepatol Int 2020;14:299-301. [PMID: 32304088 DOI: 10.1007/s12072-020-10033-1] [Reference Citation Analysis]
6 Lin Y, Yan G, Feng F, Wang M, Long F. Characterization of intestinal microbiota and serum metabolites in patients with mild hepatic encephalopathy. Open Life Sciences 2022;17:139-54. [DOI: 10.1515/biol-2021-0140] [Reference Citation Analysis]
7 Haraguchi M, Miuma S, Masumoto H, Ichikawa T, Kanda Y, Sasaki R, Fukushima M, Miyaaki H, Taura N, Nakao K. Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis. Hepatol Int 2019;13:482-9. [DOI: 10.1007/s12072-019-09963-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. J Hepatol 2021;75 Suppl 1:S36-48. [PMID: 34039491 DOI: 10.1016/j.jhep.2020.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wu J, Huang F, Ling Z, Liu S, Liu J, Fan J, Yu J, Wang W, Jin X, Meng Y, Cao H, Li L. Altered faecal microbiota on the expression of Th cells responses in the exacerbation of patients with hepatitis E infection. J Viral Hepat 2020;27:1243-52. [PMID: 32500937 DOI: 10.1111/jvh.13344] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
10 Muto H, Ito T, Tanaka T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Maeda K, Honda T, Ishikawa T, Kato A, Ohshiro T, Kano F, Yamamoto A, Sakai K, Hibi H, Ishigami M, Fujishiro M. Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis. Sci Rep 2021;11:18778. [PMID: 34548598 DOI: 10.1038/s41598-021-98254-8] [Reference Citation Analysis]
11 Sakamaki A, Kamimura K, Yokoo T, Osaki A, Yoshikawa S, Arao Y, Setsu T, Kamimura H, Waguri N, Takeuchi M, Funakoshi K, Terai S. The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan. Medicine (Baltimore) 2021;100:e26902. [PMID: 34397919 DOI: 10.1097/MD.0000000000026902] [Reference Citation Analysis]
12 Yokoyama K, Tsuchiya N, Yamauchi R, Miyayama T, Uchida Y, Shibata K, Fukuda H, Umeda K, Takata K, Tanaka T, Inomata S, Morihara D, Takeyama Y, Shakado S, Sakisaka S, Hirai F. Exploratory Research on the Relationship between Human Gut Microbiota and Portal Hypertension. Intern Med 2020;59:2089-94. [PMID: 32879200 DOI: 10.2169/internalmedicine.4628-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Dai R, Sag AA, Martin JG, Befera NT, Pabon-Ramos WM, Suhocki PV, Smith TP, Kim CY, Muir AJ, Ronald J. Proton pump inhibitor use is associated with increased rates of post-TIPS hepatic encephalopathy: Replication in an independent patient cohort. Clin Imaging 2021;77:187-92. [PMID: 33940357 DOI: 10.1016/j.clinimag.2021.04.034] [Reference Citation Analysis]
14 Liu Y, Jin X, Hong HG, Xiang L, Jiang Q, Ma Y, Chen Z, Cheng L, Jian Z, Wei Z, Ai J, Qi S, Sun Q, Li H, Li Y, Wang K. The relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease. FASEB J 2020;34:11200-14. [PMID: 32645241 DOI: 10.1096/fj.202000786R] [Cited by in F6Publishing: 1] [Reference Citation Analysis]